cell_id,prompt,answer,output70
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-24-1. The drug SMILES structure is COC1=CC(=CC(=C1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)OC. Drug target is LCK. Drug target pathway is Other, kinases.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JW-7-24-1 on the cell line as Resistant.

The drug targets LCK, which is a kinase that plays a role in the signaling pathways of T cells. The cell line has mutations in several genes that are involved in kinase signaling, including FLT3, MAP3K1, and NOTCH1. These mutations may confer resistance to the drug by altering the signaling pathways that LCK regulates. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that can regulate cell death and proliferation. Mutations in TP53 can also contribute to drug resistance.

Therefore, based on the available information, it is likely that the cell line is resistant to JW-7-24-1."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-TAE684. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of NVP-TAE684 on the cell line with the given mutations would be:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-244. The drug SMILES structure is C1=CC=C(C=C1)[C@H](COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F. Drug target is PDK1. Drug target pathway is Other, kinases.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of KIN001-244 on the cell line with the given mutations as Resistant.

The drug targets PDK1, which is not directly related to the given mutations. Moreover, the drug's target pathway, Other, kinases, does not seem to be affected by the mutations either. Therefore, it is likely that the drug will not be effective on this cell line.

So, the answer would be:

Drug Sensitivity: Resistant"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINSITINIB. The drug SMILES structure is CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Sensitive.

The drug is a tyrosine kinase inhibitor that targets IGF1R, which is mutated in the cell line. The presence of the mutation suggests that the cell line may be sensitive to the drug."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0642. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F. Drug target is G9A, GLP. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of UNC0642 on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-52-1. The drug SMILES structure is CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F. Drug target is MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would classify the drug sensitivity of JW-7-52-1 as Sensitive.

The drug targets MTOR, which is a key regulator of cell growth and metabolism, and the cell line mutations include TP53, which is a tumor suppressor gene that regulates cell growth and apoptosis. The presence of a TP53 mutation suggests that the cell line may be more sensitive to drugs that target the PI3K/MTOR signaling pathway, such as JW-7-52-1. Additionally, the presence of other mutations in genes such as FLT3, NOTCH1, and MAP3K1, which are involved in cell signaling and proliferation, may also contribute to the cell line's sensitivity to JW-7-52-1.

Therefore, based on the available information, I would classify the drug sensitivity of JW-7-52-1 as Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BOSUTINIB. The drug SMILES structure is CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC. Drug target is SRC, ABL, TEC. Drug target pathway is Other, kinases.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of BOSUTINIB on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOXORUBICIN. The drug SMILES structure is C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O. Drug target is Anthracycline. Drug target pathway is DNA replication.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of DOXORUBICIN on the cell line with the given mutations as Resistant.

The drug target of DOXORUBICIN is Anthracycline, which is a DNA-intercalating agent that inhibits DNA replication by binding to the minor groove of DNA. The drug's mechanism of action is not dependent on any specific kinase or signaling pathway, but rather works by interfering with the replication of DNA.

The cell line mutations include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, and U2AF1. None of these mutations are known to have a direct impact on the drug target or mechanism of action of DOXORUBICIN. Therefore, it is likely that the drug will still be effective against the cell line, despite the presence of these mutations.

Therefore, the drug sensitivity of DOXORUBICIN on the cell line with the given mutations is Resistant."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YK-4-279. The drug SMILES structure is COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O. Drug target is RNA helicase A. Drug target pathway is Other.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YK-4-279 on the cell line as Sensitive.

The drug targets RNA helicase A, which is not a well-established drug target in cancer treatment, and the cell line has several mutations in genes that are not typically associated with drug resistance. The presence of mutations in genes such as ASXL1, FLT3, MAP3K1, NOTCH1, TP53, and U2AF1 suggests that the cell line may be more sensitive to drugs that target other pathways.

Therefore, in a single word, I would describe the drug sensitivity of YK-4-279 on the cell line as Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0810. The drug SMILES structure is CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl. Drug target is ESR1, ESR2. Drug target pathway is Hormone-related.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of GDC-0810 on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ABT-737. The drug SMILES structure is CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would predict the drug sensitivity of ABT-737 on the cell line with the given mutations as Resistant.

The drug target of ABT-737 is unknown, and its target pathway is also unknown. Therefore, it is difficult to predict whether the drug will be effective on the cell line. However, looking at the mutations present in the cell line, there are several mutations that could potentially confer resistance to the drug. For example, the presence of a mutation in the FLT3 gene, which is involved in cell signaling pathways, could lead to increased activation of downstream signaling pathways and render the drug ineffective. Similarly, mutations in the NOTCH1 gene, which is involved in cell fate determination, could also lead to resistance to the drug.

Therefore, based on the available information, I would predict that ABT-737 would be resistant to the cell line with the given mutations."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MPS-1-IN-1. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC. Drug target is MPS1. Drug target pathway is Mitosis.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of MPS-1-IN-1 on the cell line as Sensitive.

The drug targets MPS1, which is a key regulator of mitosis, and the cell line has mutations in genes that are involved in mitotic regulation, such as TP53 and NOTCH1. Additionally, the cell line has mutations in genes that are involved in the PI3K/AKT signaling pathway, such as FLT3 and MAP3K1, which could potentially interact with the drug's mechanism of action.

Therefore, based on the available information, it is likely that MPS-1-IN-1 would be effective in inhibiting the growth of this cell line, and I would classify its drug sensitivity as Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ROSCOVITINE. The drug SMILES structure is CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3. Drug target is CDK2, CDK7, CDK9. Drug target pathway is Cell cycle.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SCH772984. The drug SMILES structure is O=C([C@H]1CN(CC(N2CCN(C3=CC=C(C4=NC=CC=N4)C=C3)CC2)=O)CC1)NC5=CC6=C(NN=C6C7=CC=NC=C7)C=C5. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of SCH772984 on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OTX015. The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C. Drug target is BRD2, BRD3, BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of OTX015 on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of YM-201636 on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TRAMETINIB. The drug SMILES structure is CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of TRAMETINIB on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PI-103. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O. Drug target is PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PI-103 on the cell line with the given mutations is Sensitive.

The drug targets multiple kinases, including PI3Kalpha, DAPK3, CLK4, PIM3, and HIPK2, which are involved in various cellular signaling pathways. The cell line mutations include ASXL1, FLT3, MAP3K1, NOTCH1, TP53, and U2AF1, which are associated with cancer and may promote resistance to certain drugs. However, the drug's ability to target multiple kinases simultaneously may overcome some of these resistance mechanisms, leading to sensitive drug sensitivity. Therefore, the drug sensitivity of PI-103 on this cell line is predicted to be Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SHIKONIN. The drug SMILES structure is CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C. Drug target is not defined. Drug target pathway is Other.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is I-BET-762. The drug SMILES structure is CCNC(=O)C[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C. Drug target is BRD2, BRD3, BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of I-BET-762 on the given cell line is:

Resistant

Explanation:

The drug I-BET-762 targets BRD2, BRD3, and BRD4, which are chromatin-modifying enzymes involved in transcriptional regulation. The cell line has mutations in genes such as TP53, NOTCH1, and FLT3, which are known to affect the activity of these enzymes. Additionally, the cell line has a mutation in U2AF1, which is involved in mRNA splicing and can affect the expression of genes involved in chromatin modification. Therefore, it is likely that the cell line has developed resistance to the drug through these mutations, leading to reduced sensitivity."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QS-11. The drug SMILES structure is C1CC2=C(C1)C=C(C=C2)OC3=NC(=C4C(=N3)N(C=N4)CC5=CC=C(C=C5)C6=CC=CC=C6)NC(CC7=CC=CC=C7)CO. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of QS-11 on the cell line with the given mutations as Resistant.

The drug QS-11 has an unknown target and pathway, which makes it difficult to predict its sensitivity based on the mutations present in the cell line. However, looking at the mutations present in the cell line, there are several mutations in genes that are involved in signaling pathways that could potentially interact with the unknown target of QS-11. For example, the presence of a mutation in the FLT3 gene, which is involved in the RTK signaling pathway, could potentially confer resistance to QS-11. Additionally, the presence of a mutation in the TP53 gene, which is a tumor suppressor gene that regulates various cellular processes, including cell cycle and apoptosis, could also contribute to resistance to QS-11.

Therefore, based on the available information, I would predict the drug sensitivity of QS-11 on the cell line with the given mutations as Resistant."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GW-843682X. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of GW-843682X on the cell line with the given mutations as Resistant.

The drug's target is unknown, and its target pathway is also unknown. Therefore, it is difficult to determine whether the drug would be effective on the cell line with the given mutations. Additionally, the cell line has mutations in genes such as TP53, which is a tumor suppressor gene that can confer resistance to chemotherapy. Therefore, it is likely that the cell line would be resistant to the drug.

So, the answer would be:

Drug Sensitivity: Resistant"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ACY-1215. The drug SMILES structure is C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO. Drug target is HDAC6. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of ACY-1215 on the given cell line is:

Sensitive

Explanation:

The drug ACY-1215 targets HDAC6, which is involved in chromatin histone acetylation. The cell line has mutations in genes such as ASXL1, FLT3, MAP3K1, NOTCH1, TP53, and U2AF1. These mutations do not seem to affect the activity of HDAC6 or its interaction with ACY-1215. Therefore, it is likely that the drug will be effective in inhibiting HDAC6 and inducing apoptosis in this cell line."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-042. The drug SMILES structure is C1=CC(=CC(=C1)I)CSC2=NN=C(O2)C3=CC=NC=C3. Drug target is GSK3B. Drug target pathway is WNT signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of KIN001-042 on the given cell line is Resistant.

The drug targets GSK3B, which is a key regulator of the WNT signaling pathway. However, the cell line has mutations in several genes that are involved in the WNT signaling pathway, including ASXL1, NOTCH1, and TP53. These mutations may disrupt the normal functioning of the WNT pathway and confer resistance to the drug. Additionally, the cell line has a mutation in FLT3, which is a tyrosine kinase that can activate the WNT pathway, and MAP3K1, which is a kinase that can also activate the WNT pathway. These mutations may also contribute to resistance to the drug.

Therefore, based on the available information, it is likely that the cell line is resistant to KIN001-042."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MITOXANTRONE. The drug SMILES structure is C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO. Drug target is TOP2. Drug target pathway is DNA replication.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NIRAPARIB. The drug SMILES structure is C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of NIRAPARIB on the given cell line is:

Sensitive"
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PIK-93. The drug SMILES structure is CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO. Drug target is PK3CG. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PIK-93 on the cell line with the given mutations is Sensitive.

The drug targets PK3CG, which is a key regulator of the PI3K/MTOR signaling pathway. The cell line has mutations in several genes that are involved in this pathway, including TP53, NOTCH1, and MAP3K1. These mutations are likely to enhance the activity of the PI3K/MTOR pathway, making the cell line more sensitive to inhibition by PIK-93.

Therefore, the drug sensitivity of PIK-93 on this cell line is Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TELOMERASE INHIBITOR IX. The drug SMILES structure is C1=CC(=CC(=C1)NC(=O)C2=C(C(=CC=C2)O)O)NC(=O)C3=C(C(=CC=C3)O)O. Drug target is Telomerase. Drug target pathway is Genome integrity.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Sensitive.

The drug is a telomerase inhibitor, and the cell line has mutations in genes related to genome integrity, such as TP53 and U2AF1. Telomerase is a key enzyme involved in maintaining telomeres, and inhibiting it can lead to cell death in cancer cells. Therefore, it is likely that the drug will be effective against this cell line, and the drug sensitivity is predicted to be Sensitive."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BRYOSTATIN-1. The drug SMILES structure is CCCC=CC=CC(=O)OC1C(=CC(=O)OC)CC2CC(OC(=O)CC(CC3CC(C(C(O3)(CC4CC(=CC(=O)OC)CC(O4)C=CC(C1(O2)O)(C)C)O)(C)C)OC(=O)C)O)C(C)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would classify the drug sensitivity of BRYOSTATIN-1 on the cell line with the given mutations as Resistant.

The drug targets Unknown, and the drug target pathway is Unknown, which suggests that the drug's mechanism of action is not well understood. Additionally, the cell line has mutations in genes such as TP53, which is a known tumor suppressor gene, and FLT3, which is a kinase that is often mutated in cancer cells. These mutations may contribute to the development of resistance to the drug.

Therefore, in a single word, the drug sensitivity of BRYOSTATIN-1 on the cell line with the given mutations would be Resistant."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WYE-125132. The drug SMILES structure is CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7. Drug target is mTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of WYE-125132 on the given cell line is:

Sensitive

Explanation:

The drug WYE-125132 targets mTOR, which is a key regulator of cell growth and metabolism. The cell line has mutations in genes such as ASXL1, FLT3, MAP3K1, NOTCH1, TP53, and U2AF1, which are known to be involved in various cellular processes, including cell signaling, apoptosis, and DNA damage response. However, none of these mutations are known to directly affect the mTOR pathway, which is the target of WYE-125132. Therefore, it is likely that the drug will still be effective in inhibiting mTOR activity in this cell line, leading to sensitive drug sensitivity."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CARMUSTINE. The drug SMILES structure is C(CCl)NC(=O)N(CCCl)N=O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of CARMUSTINE on the cell line with the given mutations as Resistant.

The drug target of CARMUSTINE is unknown, and its mechanism of action is not well understood. Therefore, it is difficult to predict whether the drug would be effective against the cell line with the given mutations. However, based on the available information, it appears that the cell line has mutations in genes that are involved in various signaling pathways, including the NOTCH1 and FLT3 pathways. These mutations may potentially confer resistance to the drug, as they may allow the cancer cells to continue to proliferate and survive even in the presence of the drug.

Therefore, in a single word, I would describe the drug sensitivity of CARMUSTINE on the cell line with the given mutations as Resistant."
ACH-000006,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-135. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C#N)OCC4=CC=CC=C4S(=O)(=O)C)OC. Drug target is IKK. Drug target pathway is Other, kinases.
The mutations of the cell line are ASXL1, FLT3, MAP3K1, NOTCH1, TP53, U2AF1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of KIN001-135 on the cell line with the given mutations is Resistant.

The drug targets IKK, which is not directly related to the given mutations in the cell line. The mutations in the cell line are primarily related to signaling pathways such as NOTCH1, FLT3, and TP53, which are not directly affected by IKK. Therefore, it is likely that the drug will not be effective on this cell line.

Here's a single word reflecting the drug sensitivity of KIN001-135 on the cell line: Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-505124. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=C(C=C3)OCO4. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of SB-505124 on the cell line as Resistant.

The drug SB-505124 has an unknown target and pathway, which makes it difficult to determine its sensitivity based on the mutations present in the cell line. However, the cell line has mutations in genes such as TP53, BRCA2, and MLL, which are known to be involved in various cellular processes, including DNA repair and cell cycle regulation. These mutations could potentially confer resistance to the drug, especially if it targets a pathway that is compromised by the mutations.

Therefore, in the absence of specific information about the drug's target and pathway, I would classify the drug sensitivity of SB-505124 on the cell line as Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZG-10. The drug SMILES structure is O=C(C1=CC=C(NC(C=CCN(C)C)=O)C=C1)NC2=CC(NC3=NC(C4=CC=CN=C4)=CC=N3)=CC=C2. Drug target is JNK1. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of ZG-10 on the cell line with the given mutations is Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-TAE684. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of NVP-TAE684 on the given cell line would be ""Sensitive"".

The drug targets the ALK protein, which is mutated in the cell line, and the drug's target pathway, RTK signaling, is also affected by the mutations in the cell line. Specifically, the ALK mutation is likely to result in constitutive activation of the receptor, leading to uncontrolled cell growth and proliferation. The presence of additional mutations in genes such as TP53, BRCA2, and MLL also suggest that the cell line may have a high level of genetic instability, which could make it more sensitive to the effects of NVP-TAE684.

Therefore, based on the available information, it is likely that NVP-TAE684 would be effective in inhibiting the growth of this cell line, and I would classify its drug sensitivity as ""Sensitive""."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAZOPANIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N. Drug target is CSF1R, KIT,  PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,Resistant
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of CAY10566 on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GDC-0941. The drug SMILES structure is CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6. Drug target is PI3K (class 1). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of GDC-0941 on the cell line with the given mutations is Sensitive.

The drug targets PI3K (class 1) and the cell line has mutations in genes such as ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53. These mutations are known to be associated with increased activity of the PI3K/MTOR signaling pathway, which is the target of GDC-0941. Therefore, it is likely that the drug will be effective in inhibiting the activity of this pathway and sensitive to the cell line.

So, the answer is: Sensitive."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ004777. The drug SMILES structure is CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would predict that the drug EPZ004777 would have a sensitive drug sensitivity profile in the cell line with the given mutations.

The drug targets DOT1L, which is a histone methyltransferase that plays a role in regulating chromatin structure and gene expression. The cell line has mutations in several genes that are involved in chromatin modification and gene expression, including BRCA2, SMARCA4, and TP53. These mutations may affect the expression of genes that are targeted by EPZ004777, leading to increased sensitivity to the drug.

Additionally, the cell line has a mutation in the KDM5C gene, which encodes a histone demethylase that is involved in regulating chromatin structure and gene expression. This mutation may also contribute to the sensitive drug sensitivity profile of EPZ004777.

Therefore, based on the available information, I would predict that EPZ004777 would have a sensitive drug sensitivity profile in the cell line with the given mutations."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TEMOZOLOMIDE. The drug SMILES structure is CN1C(=O)N2C=NC(=C2N=N1)C(=O)N. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of TEMOZOLOMIDE on the cell line with the given mutations is Resistant.

The drug targets DNA alkylating agent, which is not affected by the given mutations. Therefore, the drug is likely to be resistant to the cell line, regardless of the mutations present."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD11-85H. The drug SMILES structure is O=C1CCN(C2CCCC2)C3=NC(NC4=CC=C(C(NC5CCN(C)CC5)=O)C=C4OC)=NC=C3N1C(C)C. Drug target is LRRK2, ERK5. Drug target pathway is Other, kinases.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of XMD11-85H on the cell line as Sensitive.

The drug targets LRRK2 and ERK5, which are both involved in kinase signaling pathways. The cell line has mutations in several genes involved in kinase signaling, including ALK, AR, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53. These mutations may confer sensitivity to the drug by disrupting normal cellular signaling pathways and increasing the reliance on LRRK2 and ERK5 for cell survival. Therefore, XMD11-85H may be effective in inhibiting the activity of LRRK2 and ERK5 in this cell line, leading to cell death."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JQ1-(+). The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JQ1- (+) as Resistant.

The drug JQ1- (+) has a SMILES structure that suggests it is a bromodomain inhibitor, specifically targeting the BET protein family. However, the cell line mutations provided do not include any mutations in the BET protein family or their downstream targets. Instead, the mutations are scattered across various genes, including ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53.

Given that the drug target is Unknown and the drug target pathway is Unknown, it is difficult to determine whether the drug would be effective against the cell line. However, based on the lack of mutations in the BET protein family or their downstream targets, it is likely that the drug would not be effective against the cell line, and therefore, I would classify the drug sensitivity as Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ-5676. The drug SMILES structure is CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of EPZ-5676 on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD5363. The drug SMILES structure is O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO. Drug target is AKT1, AKT2, AKT3, ROCK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of AZD5363 on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YK-4-279. The drug SMILES structure is COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O. Drug target is RNA helicase A. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of YK-4-279 on the given cell line would be:

Sensitive

The drug targets RNA helicase A, which is not listed as a mutated gene in the cell line. Therefore, it is likely that the drug will be effective against the cell line, resulting in sensitive drug sensitivity."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LY2109761. The drug SMILES structure is C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6. Drug target is TGFB1. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LY2109761 on the cell line is Sensitive.

The drug targets TGFB1, which is a key regulator of cellular processes, including cell growth, differentiation, and survival. The cell line has several mutations in genes that are involved in TGFB1 signaling, such as ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53. These mutations may disrupt the normal regulation of TGFB1 signaling, leading to increased sensitivity to the drug.

Therefore, the drug sensitivity of LY2109761 on the cell line is Sensitive."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAP-232, TT-232, TLN-232. The drug SMILES structure is CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)O. Drug target is Glycolysis. Drug target pathway is Metabolism.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of CAP-232, TT-232, TLN-232 on the cell line as Resistant.

The drug targets glycolysis, which is a metabolic process that is not directly related to the mutations present in the cell line. The mutations in the cell line are mainly related to DNA damage response, repair, and transcriptional regulation, which are not directly connected to glycolysis. Therefore, it is unlikely that the drug will be effective in inhibiting glycolysis in this cell line, and thus, I would classify the drug sensitivity as Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CYCLOPHOSPHAMIDE. The drug SMILES structure is C1CNP(=O)(OC1)N(CCCl)CCCl. Drug target is Alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of Cyclophosphamide on the cell line with the given mutations is likely to be Resistant.

The drug targets DNA replication, and the cell line has mutations in several genes involved in DNA repair and replication, such as BRCA2, MLL, and MUTYH. These mutations may confer resistance to the drug by altering the cell's ability to repair DNA damage caused by the alkylating agent. Additionally, the presence of mutations in genes involved in other cellular processes, such as ASXL1 and SMARCA4, may also contribute to resistance to the drug.

Therefore, the drug sensitivity of Cyclophosphamide on this cell line is likely to be Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-BEZ235. The drug SMILES structure is CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5. Drug target is PI3K (class 1), MTORC1, MTORC2. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of YM-201636 on the cell line with the given mutations is Resistant.

The drug targets PIKFYVE, which is involved in the PI3K/MTOR signaling pathway. The cell line has mutations in several genes that are involved in the same pathway, including PI3K/MTOR signaling. These mutations may cause resistance to the drug by altering the target protein's activity or expression, or by activating alternative signaling pathways that can compensate for the inhibition of PIKFYVE.

Therefore, the drug sensitivity of YM-201636 on the cell line with the given mutations is Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LEFLUNOMIDE. The drug SMILES structure is CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F. Drug target is Pyrimidine synthesis inhibitor. Drug target pathway is DNA replication.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of LEFLUNOMIDE on the cell line with the given mutations is Resistant.

The drug targets the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in pyrimidine synthesis. Inhibition of DHODH by LEFLUNOMIDE leads to a decrease in the levels of pyrimidines, such as uridine and cytidine, which are essential for DNA replication and synthesis.

However, the cell line has mutations in several genes involved in DNA repair and replication, including BRCA2, MLL, MUTYH, and TP53. These mutations may confer resistance to the drug by allowing the cell to bypass the inhibition of pyrimidine synthesis and maintain DNA replication.

Therefore, based on the available information, the drug sensitivity of LEFLUNOMIDE on the cell line with the given mutations is Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-216763. The drug SMILES structure is CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl. Drug target is GSK3A, GSK3B. Drug target pathway is WNT signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of SB-216763 on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SHIKONIN. The drug SMILES structure is CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C. Drug target is not defined. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QS-11. The drug SMILES structure is C1CC2=C(C1)C=C(C=C2)OC3=NC(=C4C(=N3)N(C=N4)CC5=CC=C(C=C5)C6=CC=CC=C6)NC(CC7=CC=CC=C7)CO. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of QS-11 on the cell line with the given mutations is Resistant.

The drug target of QS-11 is unknown, and its drug target pathway is also unknown. Therefore, it is difficult to predict whether the drug will be effective on the cell line with the given mutations. However, based on the mutations listed, it appears that the cell line has mutations in genes that are involved in various cellular processes, including DNA repair, cell cycle regulation, and signaling pathways.

Some of the mutations, such as those in TP53, BRCA2, and MLL, are known to be associated with resistance to certain cancer therapies. Additionally, the presence of mutations in genes involved in DNA repair, such as MUTYH, may also contribute to resistance to chemotherapy.

Therefore, based on the available information, it is likely that QS-11 will be resistant to the cell line with the given mutations."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MOTESANIB. The drug SMILES structure is CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C. Drug target is VEGFR, RET, KIT, PDGFR. Drug target pathway is RTK signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of MOTESANIB on the cell line with the given mutations is likely to be Sensitive.

The drug targets VEGFR, RET, KIT, and PDGFR, which are all involved in RTK signaling. The cell line has mutations in several genes that are involved in the same pathway, including ALK, AR, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53. These mutations may enhance the activity of the drug targets, making the cell line more sensitive to the drug.

Therefore, the drug sensitivity of MOTESANIB on the cell line with the given mutations is likely to be Sensitive."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DACTINOMYCIN. The drug SMILES structure is C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C. Drug target is RNA polymerase. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of DACTINOMYCIN on the cell line with the given mutations is Resistant.

The drug targets RNA polymerase, which is not directly affected by the mutations listed. Therefore, the drug is unlikely to be effective against the cell line, leading to a resistant phenotype."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD13-2. The drug SMILES structure is O=C(C1CC1)NC2=NNC3=CC(C4=CC(C(NC5CC5)=O)=CC=C4)=CC=C32. Drug target is MRCKB. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of XMD13-2 on the given cell line would be ""Resistant"".

The drug XMD13-2 targets MRCKB, which is a protein involved in the cytoskeleton pathway. The cell line has mutations in several genes, including ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, and TP53. Some of these mutations are known to confer resistance to drugs that target the cytoskeleton, such as MRCKB.

Therefore, based on the available information, it is likely that the cell line is resistant to XMD13-2."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is STF-62247. The drug SMILES structure is CC1=CC(=CC=C1)NC2=NC(=CS2)C3=CC=NC=C3. Drug target is Autophagy inducer. Drug target pathway is Other.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would classify the drug sensitivity of STF-62247 on the given cell line as Sensitive.

The drug targets autophagy, which is a cellular process that helps to recycle damaged or dysfunctional cellular components. The cell line has several mutations in genes that are involved in DNA repair, cell cycle regulation, and tumor suppressor functions, such as BRCA2, MLL, and TP53. These mutations may impair the cell's ability to repair damaged DNA, leading to an accumulation of damaged cellular components. Autophagy is a mechanism that can help to remove these damaged components, and therefore, the drug may be effective in inducing autophagy in this cell line.

Additionally, the drug's mechanism of action, which involves inhibiting the activity of a protein called ATG4B, may also contribute to its effectiveness in this cell line. ATG4B is a key regulator of autophagy, and its inhibition can lead to an increase in autophagic activity.

Overall, based on the available information, I would predict that STF-62247 would be effective in inducing autophagy and killing the cancer cells in this cell line, and therefore, classify its drug sensitivity as Sensitive."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CCT018159. The drug SMILES structure is CCC1=CC(=C(C=C1O)O)C2=NNC(=C2C3=CC4=C(C=C3)OCCO4)C. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of CCT018159 on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VENETOCLAX. The drug SMILES structure is CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C. Drug target is BCL2. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of VENETOCLAX on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ELESCLOMOL. The drug SMILES structure is CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of ELESCLOMOL on the given cell line is:

Sensitive"
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK2578215A. The drug SMILES structure is C1=CC=C(C=C1)COC2=C(C=C(C=C2)C3=CC(=NC=C3)F)C(=O)NC4=CN=CC=C4. Drug target is LRRK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of GSK2578215A on the cell line with the given mutations is Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BIX02189. The drug SMILES structure is CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O. Drug target is MEK5, ERK5. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of BIX02189 on the cell line with the given mutations is Resistant.

The drug targets MEK5 and ERK5, which are part of the ERK MAPK signaling pathway. The cell line has mutations in several genes that are involved in the same pathway, including ALK, AR, ATR, BRCA2, KDM5C, MLL, MUTYH, and TP53. These mutations may cause resistance to the drug by altering the signaling pathway and reducing its effectiveness.

Therefore, the drug sensitivity of BIX02189 on this cell line is Resistant."
ACH-000021,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-135. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C#N)OCC4=CC=CC=C4S(=O)(=O)C)OC. Drug target is IKK. Drug target pathway is Other, kinases.
The mutations of the cell line are ALK, AR, ASXL1, ATR, BRCA2, CSF1R, KDM5C, MLL, MUTYH, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of KIN001-135 on the cell line with the given mutations is Resistant.

The drug targets IKK, which is not directly related to the given mutations. Moreover, the cell line has mutations in genes such as TP53, MLL, and BRCA2, which are known to be involved in DNA repair and cell cycle regulation. These mutations may confer resistance to the drug's activity. Therefore, the drug sensitivity is predicted to be Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JW-7-24-1. The drug SMILES structure is COC1=CC(=CC(=C1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)OC. Drug target is LCK. Drug target pathway is Other, kinases.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JW-7-24-1 on the cell line with the given mutations as Resistant.

The drug targets LCK, which is a kinase that plays a role in T cell signaling. The cell line has mutations in genes such as IRS2 and NBN, which are involved in signaling pathways downstream of LCK. These mutations may confer resistance to the drug by altering the signaling pathways that JW-7-24-1 targets. Additionally, the cell line has a mutation in WHSC1L1, which is a histone methyltransferase that has been implicated in the regulation of gene expression and cell proliferation. This mutation may also contribute to resistance to the drug.

Therefore, based on the available information, I would predict that JW-7-24-1 would be resistant to the cell line with the given mutations."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ERK5-IN-1. The drug SMILES structure is CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCN(CC3)C)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C7CCCC7. Drug target is ERK5, BET. Drug target pathway is Other.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of ERK5-IN-1 on the cell line with the given mutations as Sensitive.

The drug targets ERK5 and BET, which are both involved in signaling pathways that regulate cellular processes such as proliferation, differentiation, and survival. The cell line mutations include ARFRP1, IRS2, NBN, and WHSC1L1, which are involved in various cellular processes, including signaling pathways that may interact with the drug target pathways.

Given that the drug targets are not directly affected by the cell line mutations, it is likely that the drug will still be effective in inhibiting its targets and producing a therapeutic effect. Therefore, I would classify the drug sensitivity of ERK5-IN-1 on this cell line as Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IMATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL, KIT, PDGFR. Drug target pathway is Other, kinases.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of IMATINIB on the cell line with the given mutations is Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CX-5461. The drug SMILES structure is CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C. Drug target is RNA Polymerase 1. Drug target pathway is Other.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of CX-5461 on the cell line with mutations in ARFRP1, IRS2, NBN, and WHSC1L1 would be Resistant.

This is because CX-5461 targets RNA Polymerase 1, which is not directly affected by the mutations in the cell line. The mutations in the cell line are in genes that are involved in various signaling pathways, but they do not directly impact the activity of RNA Polymerase 1. Therefore, the drug would not be effective in inhibiting the activity of RNA Polymerase 1 in this cell line, and the sensitivity would be Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NVP-TAE684. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC. Drug target is ALK. Drug target pathway is RTK signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of NVP-TAE684 on the cell line with the given mutations is Sensitive.

The drug targets ALK, which is a receptor tyrosine kinase that plays a crucial role in cellular signaling pathways, including RTK signaling. The cell line has mutations in genes that are involved in the same signaling pathway, such as IRS2 and NBN. These mutations may enhance the activity of ALK and increase the sensitivity of the cell line to NVP-TAE684.

Therefore, the drug sensitivity of NVP-TAE684 on the cell line with the given mutations is Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-244. The drug SMILES structure is C1=CC=C(C=C1)[C@H](COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F. Drug target is PDK1. Drug target pathway is Other, kinases.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of KIN001-244 on the cell line with the given mutations as Resistant.

The drug targets PDK1, which is a key regulator of cellular signaling pathways, including the PI3K/AKT and MAPK pathways. The cell line has mutations in genes that are involved in these pathways, such as IRS2 and NBN, which could potentially confer resistance to the drug. Additionally, the cell line has a mutation in WHSC1L1, which has been associated with resistance to PI3K inhibitors.

Therefore, based on the available information, it is likely that the cell line with these mutations would be resistant to KIN001-244."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINSITINIB. The drug SMILES structure is CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LINSITINIB on the cell line with the given mutations is Sensitive.

The drug targets IGF1R, which is a key regulator of cell growth and survival. The cell line has mutations in genes that are downstream of IGF1R, including IRS2 and WHSC1L1. These mutations are likely to enhance the activity of IGF1R, making the cell line more dependent on this pathway. Therefore, inhibition of IGF1R by LINSITINIB is likely to be effective in inhibiting the growth of this cell line.

Additionally, the cell line has a mutation in NBN, which is a negative regulator of IGF1R. This mutation may reduce the ability of NBN to inhibit IGF1R, making the cell line more sensitive to the inhibitory effects of LINSITINIB.

Overall, based on the drug target and the mutations present in the cell line, it is likely that LINSITINIB will be effective in inhibiting the growth of this cell line, and therefore the drug sensitivity is classified as Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTY-720. The drug SMILES structure is CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N. Drug target is S1P. Drug target pathway is Other.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of FTY-720 on the cell line as Resistant.

The drug targets S1P, which is not a kinase or a protein that regulates protein stability and degradation. Therefore, it is unlikely that the mutations in the cell line, which are mainly related to kinases and protein stability, would have a significant impact on the drug's efficacy.

Additionally, FTY-720 has a chemical structure that is different from the other drugs in the examples provided, which suggests that it may have a different mechanism of action. Therefore, it is possible that the drug may not be affected by the mutations in the cell line, leading to resistance.

Therefore, my answer would be:

Drug Sensitivity: Resistant"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0642. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F. Drug target is G9A, GLP. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of UNC0642 on the cell line with the given mutations is:

Sensitive"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AS601245. The drug SMILES structure is C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4. Drug target is JNK1, JNK2, JNK2. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of AS601245 on the cell line as Resistant.

The drug targets JNK1, JNK2, and JNK2, which are involved in the JNK and p38 signaling pathways. However, the cell line has mutations in genes such as ARFRP1, IRS2, NBN, and WHSC1L1, which are not directly related to the JNK and p38 signaling pathways. Therefore, it is unlikely that the drug will be effective in inhibiting the JNK and p38 signaling pathways in this cell line, leading to resistance to the drug."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOXORUBICIN. The drug SMILES structure is C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O. Drug target is Anthracycline. Drug target pathway is DNA replication.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of DOXORUBICIN on the cell line with the given mutations is Sensitive.

The drug targets the Anthracycline pathway, which is involved in DNA replication. The cell line has mutations in genes such as ARFRP1, IRS2, NBN, and WHSC1L1, which are not directly related to the Anthracycline pathway. Therefore, it is likely that the drug will still be effective in inhibiting DNA replication and inducing cell death in this cell line.

So, the answer is:

Sensitive"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YK-4-279. The drug SMILES structure is COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O. Drug target is RNA helicase A. Drug target pathway is Other.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YK-4-279 on the cell line with the given mutations as Resistant.

The drug targets RNA helicase A, which is not a well-established drug target for cancer treatment, and the cell line has several mutations in genes that are not directly related to the drug target or its pathway. Therefore, it is unlikely that the drug would be effective in this cell line, and I would predict resistance to the drug."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NPK76-II-72-1. The drug SMILES structure is CC1CC(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C. Drug target is PLK3. Drug target pathway is Cell cycle.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of NPK76-II-72-1 on the cell line with the given mutations as Resistant.

The drug targets PLK3, which is involved in the cell cycle pathway. The cell line has mutations in genes such as IRS2 and NBN, which are also involved in the cell cycle pathway. These mutations may confer resistance to the drug by altering the cell's ability to respond to PLK3 inhibition. Additionally, the presence of a mutation in WHSC1L1, which is involved in transcriptional regulation, may also contribute to resistance by altering the expression of genes involved in the cell cycle pathway.

Therefore, based on the available information, I would predict that the drug NPK76-II-72-1 would be resistant to the cell line with the given mutations."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ABT-737. The drug SMILES structure is CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of ABT-737 on the cell line with the given mutations as Resistant.

The drug ABT-737 is a Bcl-2 family inhibitor that targets multiple proteins, including Bcl-2, Bcl-xL, and Mcl-1. However, the specific drug target and target pathway are not specified in the given information.

The cell line has mutations in genes such as ARFRP1, IRS2, NBN, and WHSC1L1. These mutations do not seem to be related to the drug target or target pathway of ABT-737, and therefore, it is unlikely that they would have a significant impact on the drug's efficacy.

Therefore, based on the available information, I would determine the drug sensitivity of ABT-737 on the cell line with the given mutations as Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MPS-1-IN-1. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC. Drug target is MPS1. Drug target pathway is Mitosis.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of MPS-1-IN-1 on the cell line with mutations in ARFRP1, IRS2, NBN, and WHSC1L1 would be ""Sensitive""."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SB-525334. The drug SMILES structure is CC1=NC(=CC=C1)C2=C(N=C(N2)C(C)(C)C)C3=CC4=NC=CN=C4C=C3. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of SB-525334 on the cell line with the given mutations as Resistant.

The drug's target pathway is Unknown, and it does not seem to be related to any of the mutated genes in the cell line. Therefore, it is unlikely that the drug would be effective in inhibiting the growth of this cell line."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ROSCOVITINE. The drug SMILES structure is CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3. Drug target is CDK2, CDK7, CDK9. Drug target pathway is Cell cycle.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of ROSCOVITINE on the cell line with the given mutations is Sensitive.

The drug targets CDK2, CDK7, and CDK9, which are all involved in the cell cycle pathway. The cell line has mutations in ARFRP1, IRS2, NBN, and WHSC1L1, which do not seem to affect the drug's target pathway. Therefore, it is likely that the drug will still be effective in inhibiting the cell cycle and causing cell death in this cell line.

So, the answer is: Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FH-535. The drug SMILES structure is CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of FH-535 on the cell line with the given mutations as Resistant.

The drug FH-535 has an unknown target and pathway, which makes it difficult to predict its sensitivity. However, based on the mutations present in the cell line, it is likely that the drug will not be effective. The cell line has mutations in genes such as ARFRP1, IRS2, NBN, and WHSC1L1, which are not known to be involved in the target pathway of FH-535. Therefore, it is unlikely that the drug will be able to effectively target and inhibit its intended target, leading to resistance.

Therefore, the drug sensitivity of FH-535 on the cell line with the given mutations is Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TASELISIB. The drug SMILES structure is CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C. Drug target is PI3K (beta sparing). Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of TASELISIB on the cell line with the given mutations is Sensitive.

The drug targets PI3K (beta sparing), which is a key regulator of cell survival and proliferation. The cell line has mutations in genes that are downstream of PI3K, such as IRS2 and WHSC1L1, which suggests that the cell line may be dependent on the PI3K pathway for survival. Additionally, the cell line has a mutation in NBN, which is a negative regulator of PI3K, suggesting that the cell line may have increased activity of PI3K. Therefore, inhibition of PI3K by TASELISIB may be effective in inhibiting the growth of this cell line.

Therefore, the drug sensitivity of TASELISIB on this cell line is Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BLEOMYCIN. The drug SMILES structure is CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H](C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O. Drug target is dsDNA break induction. Drug target pathway is DNA replication.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of BLEOMYCIN on the cell line with the given mutations as Resistant.

The drug target of BLEOMYCIN is dsDNA break induction, which is not directly related to the mutations present in the cell line. The mutations in the cell line are ARFRP1, IRS2, NBN, and WHSC1L1, which are not known to play a direct role in DNA replication or repair. Therefore, it is unlikely that the cell line would be sensitive to BLEOMYCIN, which works by inducing DNA double-strand breaks.

Hence, the drug sensitivity of BLEOMYCIN on the cell line with the given mutations would be Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YM-201636 on the cell line with the given mutations as Resistant.

The drug targets PIKFYVE, which is involved in the PI3K/MTOR signaling pathway. The cell line has mutations in genes such as IRS2 and NBN, which are also involved in this pathway. These mutations may confer resistance to the drug by altering the activity of the target protein or downstream signaling pathways, making the cancer cells less sensitive to the drug's effects.

Therefore, based on the available information, I would classify the drug sensitivity of YM-201636 on this cell line as Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LEFLUNOMIDE. The drug SMILES structure is CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F. Drug target is Pyrimidine synthesis inhibitor. Drug target pathway is DNA replication.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of LEFLUNOMIDE on the cell line with the given mutations as Resistant.

The drug targets the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in pyrimidine synthesis. The cell line mutations include ARFRP1, IRS2, NBN, and WHSC1L1, which are not known to affect the DHODH pathway or the sensitivity of the cell line to LEFLUNOMIDE. Therefore, it is likely that the cell line would be resistant to the drug."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VOXTALISIB. The drug SMILES structure is CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N. Drug target is PI3K (class 1), DNAPK, MTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of VOXTALISIB on the cell line with the given mutations is Sensitive.

The drug targets PI3K (class 1), DNAPK, and MTOR, which are all key players in the PI3K/MTOR signaling pathway. The cell line has mutations in ARFRP1, IRS2, NBN, and WHSC1L1, which are all involved in the same signaling pathway. Therefore, it is likely that the drug will be effective in inhibiting the activity of the mutated proteins and inducing cell death in the cell line.

Hence, the drug sensitivity of VOXTALISIB on the cell line with the given mutations is Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FORETINIB. The drug SMILES structure is COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F. Drug target is MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR. Drug target pathway is RTK signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of FORETINIB on the cell line with the given mutations is Sensitive.

The drug targets multiple receptors involved in RTK signaling, including MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, and EGFR. The cell line has mutations in genes that are involved in RTK signaling, such as IRS2 and NBN, which may enhance the sensitivity of the cell line to FORETINIB. Additionally, the cell line has a mutation in WHSC1L1, which has been associated with increased sensitivity to RTK inhibitors. Therefore, it is likely that FORETINIB would be effective in inhibiting the growth of this cell line."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QS-11. The drug SMILES structure is C1CC2=C(C1)C=C(C=C2)OC3=NC(=C4C(=N3)N(C=N4)CC5=CC=C(C=C5)C6=CC=CC=C6)NC(CC7=CC=CC=C7)CO. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of QS-11 on the cell line with the given mutations as Resistant.

The drug target of QS-11 is unknown, and its drug target pathway is also unknown. Therefore, it is difficult to determine whether the drug will be effective on the cell line with the given mutations. However, based on the information provided, it appears that the cell line has mutations in genes that are involved in various cellular processes, including cell signaling and chromatin remodeling.

Given the lack of information on the drug target and target pathway, it is unlikely that QS-11 will be effective on this cell line. Therefore, I would classify the drug sensitivity of QS-11 on this cell line as Resistant."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GW-843682X. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of GW-843682X on the cell line with the given mutations as Resistant.

The drug's target and target pathway are unknown, which suggests that it may not be effective on the cell line with the given mutations. Additionally, the cell line has mutations in genes such as IRS2 and NBN, which are involved in signaling pathways that may not be affected by the drug. Therefore, it is likely that the drug will not be effective on this cell line.

So, the answer would be:

Drug Sensitivity: Resistant"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-042. The drug SMILES structure is C1=CC(=CC(=C1)I)CSC2=NN=C(O2)C3=CC=NC=C3. Drug target is GSK3B. Drug target pathway is WNT signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of KIN001-042 on the cell line as Sensitive.

The drug targets GSK3B, which is a key regulator of the WNT signaling pathway. The cell line has mutations in genes that are involved in the WNT signaling pathway, such as ARFRP1, IRS2, and NBN. These mutations may enhance the activity of the WNT pathway and increase the dependence of the cell line on GSK3B. Therefore, inhibition of GSK3B by KIN001-042 may be particularly effective in this cell line.

Additionally, the drug's mechanism of action, which involves inhibiting the activity of GSK3B, is consistent with the cell line's mutations and suggests that the drug may be effective in this context.

Therefore, based on the available information, I would predict that KIN001-042 would be sensitive in this cell line."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QUIZARTINIB. The drug SMILES structure is CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3. Drug target is FLT3. Drug target pathway is RTK signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of QUIZARTINIB on the cell line with mutations in ARFRP1, IRS2, NBN, and WHSC1L1 would be Sensitive.

The drug targets the FLT3 receptor, which is mutated in the cell line, and the drug's mechanism of action is to inhibit the activity of this receptor. Therefore, it is likely that the drug will be effective in inhibiting the activity of the mutated FLT3 receptor in this cell line, leading to sensitive drug sensitivity."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PIK-93. The drug SMILES structure is CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO. Drug target is PK3CG. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PIK-93 on the cell line with the given mutations is likely to be Sensitive.

The drug targets PK3CG, which is a key regulator of the PI3K/MTOR signaling pathway. The cell line has mutations in genes that are involved in this pathway, such as IRS2 and NBN. These mutations may enhance the activity of the PI3K/MTOR pathway, making the cell line more sensitive to inhibition by PIK-93.

Therefore, the drug sensitivity of PIK-93 on this cell line is likely to be Sensitive."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TELOMERASE INHIBITOR IX. The drug SMILES structure is C1=CC(=CC(=C1)NC(=O)C2=C(C(=CC=C2)O)O)NC(=O)C3=C(C(=CC=C3)O)O. Drug target is Telomerase. Drug target pathway is Genome integrity.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of TELOMERASE INHIBITOR IX on the cell line with the given mutations is unknown.

The drug targets telomerase, which is not directly related to the given mutations. Therefore, it is unclear whether the drug would be effective on this cell line. Further research or experimentation would be necessary to determine the drug sensitivity of TELOMERASE INHIBITOR IX on this cell line.

Therefore, the answer is:

Drug Sensitivity: Unknown"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VELIPARIB. The drug SMILES structure is C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of VELIPARIB on the given cell line is:

Sensitive"
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WYE-125132. The drug SMILES structure is CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7. Drug target is mTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of WYE-125132 on the cell line with mutations in ARFRP1, IRS2, NBN, and WHSC1L1 would be ""Sensitive"".

The drug targets mTOR, which is a key regulator of cell growth and metabolism, and the mutations in the cell line are not likely to affect the drug's activity. Therefore, it is likely that the drug will be effective in inhibiting mTOR activity in this cell line, leading to sensitive drug sensitivity."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VX-702. The drug SMILES structure is C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F. Drug target is p38. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of VX-702 on the cell line with the given mutations is Resistant.

The drug VX-702 targets the p38 protein, which is a key regulator of the JNK and p38 signaling pathways. The cell line has mutations in genes that are involved in these pathways, such as IRS2 and NBN, which may affect the drug's efficacy. Additionally, the cell line has a mutation in the WHSC1L1 gene, which has been associated with resistance to p38 inhibitors. Therefore, it is likely that the cell line is resistant to VX-702."
ACH-000045,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LUMINESPIB. The drug SMILES structure is CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ARFRP1, IRS2, NBN, WHSC1L1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of LUMINESPIB on the cell line with the given mutations as Resistant.

The drug targets HSP90, which is a protein that plays a role in protein stability and degradation. The cell line has mutations in genes that are involved in various cellular processes, including signaling pathways, gene expression, and protein degradation. However, none of the mutations directly affect the HSP90 protein or its interaction with LUMINESPIB. Therefore, it is likely that the drug will still be able to bind to its target and exert its therapeutic effect, despite the presence of these mutations.

Therefore, the drug sensitivity of LUMINESPIB on the cell line with the given mutations is Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CGP-082996. The drug SMILES structure is CCNC1=CC(=NC(=N1)NC2=CC3=C(C=C2)N(C=C3)CC4=CC=CC=C4)NC5CCC(CC5)O. Drug target is CDK4. Drug target pathway is Cell cycle.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of CGP-082996 on the cell line with the given mutations is:

Sensitive"
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AST-1306. The drug SMILES structure is C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl. Drug target is EGFR, ERBB4. Drug target pathway is RTK signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of AST-1306 on the cell line is Resistant.

The drug targets EGFR and ERBB4, which are both involved in the RTK signaling pathway. However, the cell line has mutations in several genes that are downstream of EGFR and ERBB4 in the RTK signaling pathway, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations may confer resistance to the drug by disrupting the signaling pathway and preventing the drug from effectively inhibiting its target. Therefore, the drug sensitivity of AST-1306 on this cell line is Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CX-5461. The drug SMILES structure is CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C. Drug target is RNA Polymerase 1. Drug target pathway is Other.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of CX-5461 on the cell line as Resistant.

The drug targets RNA Polymerase 1, which is not a kinase or a protein that is typically targeted by drugs in cancer treatment. Therefore, it is unlikely that the cell line's mutations in kinases such as ARAF, BTK, and MTOR would have a significant impact on the drug's efficacy. Additionally, the cell line's mutations in genes such as TP53, which is a tumor suppressor gene, may actually confer resistance to the drug.

Therefore, based on the information provided, I would predict that CX-5461 would be resistant to the cell line's mutations and would not be effective in treating cancer cells with these mutations."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of CAY10566 on the cell line as Resistant.

The drug targets Stearoyl-CoA desaturase, which is not a well-established cancer target, and the cell line has mutations in genes such as TP53, MTOR, and SMARCA4, which are known to be involved in cancer development and progression. Therefore, it is unlikely that the drug would be effective in this cell line."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NPK76-II-72-1. The drug SMILES structure is CC1CC(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C. Drug target is PLK3. Drug target pathway is Cell cycle.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of NPK76-II-72-1 on the cell line as Sensitive.

The drug targets PLK3, which is involved in the cell cycle pathway. The cell line has mutations in several genes that are involved in the same pathway, including CDKN2A, CDKN1A, and CDKN1B. These mutations may enhance the activity of PLK3, making the cell line more sensitive to the drug. Additionally, the cell line has a mutation in TP53, which is a tumor suppressor gene that regulates the cell cycle and can increase the sensitivity of cancer cells to drugs.

Therefore, based on the available information, it is likely that NPK76-II-72-1 would be effective against the cell line, and I would classify its drug sensitivity as Sensitive."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PYRIDOSTATIN. The drug SMILES structure is C1=CC=C2C(=C1)C(=CC(=N2)NC(=O)C3=CC(=CC(=N3)C(=O)NC4=NC5=CC=CC=C5C(=C4)OCCN)OCCN)OCCN. Drug target is G-quadruplex stabiliser. Drug target pathway is DNA replication.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of PYRIDOSTATIN on the cell line as Resistant.

The drug targets G-quadruplex stabiliser, which is involved in DNA replication. However, the cell line has mutations in several genes involved in DNA repair and replication, such as ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations may confer resistance to the drug by altering the target pathway, leading to reduced efficacy. Therefore, I would classify the drug sensitivity of PYRIDOSTATIN on this cell line as Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FR-180204. The drug SMILES structure is C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of FR-180204 on the given cell line would be ""Sensitive"".

The drug targets ERK1 and ERK2, which are key players in the ERK MAPK signaling pathway. The cell line has mutations in several genes that are involved in this pathway, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations may activate the ERK MAPK pathway and make the cells more sensitive to FR-180204.

Therefore, based on the available information, it is likely that the drug FR-180204 would be effective against the cell line, and I would classify its drug sensitivity as ""Sensitive""."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BVD-523. The drug SMILES structure is CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of BVD-523 on the cell line as Sensitive.

The drug targets ERK1 and ERK2, which are key components of the ERK MAPK signaling pathway. The cell line has mutations in several genes that are involved in this pathway, including MTOR, EGFR, and BTK. These mutations are likely to activate the ERK MAPK pathway and make the cells more sensitive to BVD-523.

Additionally, the drug's mechanism of action, which involves inhibiting the activity of ERK1 and ERK2, is likely to be effective against cells with activating mutations in the ERK MAPK pathway. Therefore, I would predict that BVD-523 would be sensitive on this cell line."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CETUXIMAB. The drug SMILES structure is CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of CETUXIMAB on the cell line as Resistant.

The drug targets EGFR, which is mutated in the cell line, suggesting that the drug may not be effective in inhibiting the target protein. Additionally, there are several other mutations in the cell line that could potentially confer resistance to the drug, such as mutations in the PI3K/AKT signaling pathway (MTOR, P53), which could activate alternative signaling pathways and reduce the drug's effectiveness. Therefore, I would classify the drug sensitivity of CETUXIMAB on this cell line as Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KOBE2602. The drug SMILES structure is C1=CC(=CC=C1NC(=S)NNC2=C(C=C(C=C2[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-])F. Drug target is RAS effector. Drug target pathway is RTK signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of KOBE2602 on the given cell line is:

Sensitive"
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JNJ-38877605. The drug SMILES structure is CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JNJ-38877605 on the cell line as Resistant.

The drug's target pathway is Unknown, and it has a SMILES structure that does not match any known drug targets. Additionally, the cell line has several mutations in genes that are involved in various signaling pathways, including ARAF, BTK, EGFR, MTOR, and TP53. These mutations may confer resistance to the drug, as they can potentially disrupt the drug's mechanism of action or alter the cell's response to the drug. Therefore, it is likely that the drug will not be effective against the cell line."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PFI-3. The drug SMILES structure is C1C2CN(C1CN2C3=CC=CC=N3)C=CC(=O)C4=CC=CC=C4O. Drug target is PB1, SMARCA4, SMARCA2. Drug target pathway is Chromatin other.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of PFI-3 on the cell line as Resistant.

The drug PFI-3 targets the proteins PB1, SMARCA4, and SMARCA2, which are involved in chromatin remodeling and transcriptional regulation. The cell line has mutations in several genes, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53.

Some of these mutations, such as those in ARAF, BTK, and EGFR, have been associated with resistance to drugs that target chromatin remodeling complexes. Additionally, the presence of a TP53 mutation can also contribute to drug resistance.

Therefore, based on the available information, it is likely that the cell line is resistant to PFI-3."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD3759. The drug SMILES structure is C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BAY-61-3606. The drug SMILES structure is COC1=C(C=C(C=C1)C2=CC3=NC=CN3C(=N2)NC4=C(C=CC=N4)C(=O)N)OC. Drug target is SYK. Drug target pathway is Other, kinases.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of BAY-61-3606 on the cell line with the given mutations is Resistant.

The drug targets SYK, which is not directly related to any of the mutated genes. Therefore, it is unlikely that the drug will be effective against the cell line."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is C-75. The drug SMILES structure is CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O. Drug target is FAS. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of C-75 on the cell line as Resistant.

The drug C-75 targets FAS, which is a key regulator of apoptosis. However, the cell line has mutations in several genes that are involved in apoptosis regulation, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations may confer resistance to C-75-induced apoptosis, making the drug less effective in killing the cancer cells. Therefore, I would classify the drug sensitivity of C-75 on this cell line as Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YM-201636 on the cell line as Resistant.

The drug targets PIKFYVE, which is involved in the PI3K/MTOR signaling pathway. The cell line has mutations in several genes that are also involved in this pathway, including EGFR, MTOR, and P53. These mutations may confer resistance to the drug by altering the signaling pathway and reducing its effectiveness. Additionally, the cell line has mutations in other genes that may also contribute to drug resistance, such as BTK and FLT1.

Therefore, based on the available information, it is likely that YM-201636 would be resistant to the cell line."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALVOCIDIB. The drug SMILES structure is CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of ALVOCIDIB on the cell line as Resistant.

The drug targets Unknown, and the drug target pathway is Unknown, which suggests that the drug's mechanism of action is not well understood. Additionally, the cell line has several mutations in genes that are involved in various signaling pathways, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations could potentially confer resistance to the drug.

Therefore, in a single word, the drug sensitivity of ALVOCIDIB on the cell line would be Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PANOBINOSTAT. The drug SMILES structure is CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO. Drug target is HDAC. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PANOBINOSTAT on the cell line with the given mutations is Sensitive.

The drug targets HDAC, which is involved in chromatin histone acetylation, and the cell line has mutations in genes that are involved in various signaling pathways, including the PI3K/MTOR pathway (MTOR, PI3KCA, PTEN), the ERK MAPK pathway (EGFR, BRAF, MEKK3), and the NF-κB pathway (DOT1L, TP53). These mutations suggest that the cell line may have altered epigenetic regulation and increased proliferation, which could make it more sensitive to HDAC inhibition by PANOBINOSTAT. Therefore, the drug sensitivity of PANOBINOSTAT on this cell line is predicted to be Sensitive."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VNLG/124. The drug SMILES structure is CCCC(=O)OCC1=CC=C(C=C1)OC(=O)C=C(C)C=CC=C(C)C=CC2=C(CCCC2(C)C)C. Drug target is HDAC,RAR. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of VNLG/124 on the cell line as Sensitive.

The drug VNLG/124 targets HDAC and RAR, which are both involved in chromatin histone acetylation. The cell line has mutations in genes such as ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. These mutations are not directly related to the drug target or its pathway, and therefore, they are unlikely to affect the drug's efficacy.

Therefore, based on the information provided, I would classify the drug sensitivity of VNLG/124 on the cell line as Sensitive."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK2606414. The drug SMILES structure is CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F. Drug target is PERK. Drug target pathway is Metabolism.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of GSK2606414 on the cell line with the given mutations is Sensitive.

The drug targets PERK, which is a key regulator of the unfolded protein response (UPR) pathway. The UPR pathway is activated in response to cellular stress caused by the accumulation of misfolded proteins in the endoplasmic reticulum (ER). The mutations in the cell line, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53, are known to affect various cellular processes, including signaling pathways, transcriptional regulation, and protein synthesis. However, none of these mutations are known to directly affect the PERK-mediated UPR pathway.

Therefore, it is likely that the cell line with these mutations would still be sensitive to GSK2606414, which targets the PERK-mediated UPR pathway."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PALBOCICLIB. The drug SMILES structure is CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C. Drug target is CDK4, CDK6. Drug target pathway is Cell cycle.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of PALBOCICLIB on the cell line as Sensitive.

The drug targets CDK4 and CDK6, which are key regulators of the cell cycle. The cell line has mutations in genes that are involved in the cell cycle, such as EGFR, MTOR, and TP53. These mutations may make the cell line more sensitive to the inhibition of CDK4 and CDK6 by PALBOCICLIB, leading to increased cell death. Additionally, the cell line has a mutation in the SMARCA4 gene, which has been associated with increased sensitivity to CDK4/6 inhibitors.

Therefore, based on the available information, I would predict that PALBOCICLIB would be effective in inhibiting the growth of this cell line and would classify its drug sensitivity as Sensitive."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AGI-5198. The drug SMILES structure is CC1=CC=CC=C1C(C(=O)NC2CCCCC2)N(C3=CC(=CC=C3)F)C(=O)CN4C=CN=C4C. Drug target is IDH1 (R132H). Drug target pathway is Metabolism.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of AGI-5198 on the cell line with the given mutations is Resistant.

The drug AGI-5198 targets IDH1 (R132H), which is a metabolic enzyme involved in the citric acid cycle. The cell line has mutations in several genes that are involved in signaling pathways, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. However, none of these mutations are in the same pathway as IDH1, and therefore, it is unlikely that they would affect the activity of AGI-5198.

Therefore, based on the information provided, it is likely that the cell line would be resistant to treatment with AGI-5198."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is T-0901317. The drug SMILES structure is C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of T-0901317 on the cell line as Resistant.

The drug's target pathway is Unknown, and it has a SMILES structure that suggests it is a sulfonamide-containing compound. Sulfonamides are known to have a wide range of biological activities, but their specific mechanism of action is often dependent on the target protein. In this case, the drug's target is Unknown, which suggests that its mechanism of action may not be well understood.

The cell line has a number of mutations in genes that are involved in various signaling pathways, including ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, and TP53. Some of these genes are known to be involved in resistance to certain drugs, such as EGFR and MTOR.

Given the lack of information on the drug's target and mechanism of action, and the presence of mutations in genes that can confer drug resistance, it is likely that T-0901317 would be resistant to the cell line. Therefore, the drug sensitivity of T-0901317 on the cell line would be Resistant."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BRYOSTATIN-1. The drug SMILES structure is CCCC=CC=CC(=O)OC1C(=CC(=O)OC)CC2CC(OC(=O)CC(CC3CC(C(C(O3)(CC4CC(=CC(=O)OC)CC(O4)C=CC(C1(O2)O)(C)C)O)(C)C)OC(=O)C)O)C(C)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of BRYOSTATIN-1 on the cell line with the given mutations as Resistant.

The drug targets Unknown, and its target pathway is Unknown. Therefore, it is unclear whether the drug would be effective in this cell line. Additionally, the cell line has mutations in genes such as TP53, which is a tumor suppressor gene that can lead to resistance to chemotherapy. Therefore, it is likely that the cell line would be resistant to BRYOSTATIN-1.

So, the answer would be:

Drug Sensitivity: Resistant"
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WYE-125132. The drug SMILES structure is CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7. Drug target is mTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of WYE-125132 on the given cell line is:

Sensitive

The drug targets mTOR, which is a key regulator of cell growth and proliferation, and the cell line has mutations in genes that are downstream of mTOR in the PI3K/MTOR signaling pathway, such as ARAF, EGFR, and TP53. Additionally, the cell line has a mutation in SMARCA4, which is a chromatin remodeler that can interact with mTOR. Therefore, it is likely that the drug will be effective in inhibiting the mTOR pathway in this cell line, leading to sensitive drug sensitivity."
ACH-000067,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BIX02189. The drug SMILES structure is CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O. Drug target is MEK5, ERK5. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ARAF, BTK, DOT1L, EGFR, ETV5, FLT1, MTOR, NPM1, SMARCA4, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of BIX02189 on the cell line as Resistant.

The drug targets MEK5 and ERK5, which are part of the ERK MAPK signaling pathway. The cell line has mutations in several genes that are involved in this pathway, including EGFR, MTOR, and TP53. These mutations may activate the ERK pathway and make the cells less sensitive to BIX02189, which inhibits the downstream targets MEK5 and ERK5. Therefore, I would predict that the drug would not be effective in inhibiting the growth of these cells."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WIKI4. The drug SMILES structure is COC1=CC=C(C=C1)N2C(=NN=C2SCCCN3C(=O)C4=CC=CC5=C4C(=CC=C5)C3=O)C6=CC=NC=C6. Drug target is TNKS1, TNKS2. Drug target pathway is WNT signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of WIKI4 on the cell line as Sensitive.

The drug targets TNKS1 and TNKS2, which are involved in the WNT signaling pathway. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which are genes that are also involved in the WNT signaling pathway. Therefore, it is likely that the cell line is sensitive to the drug.

Here's a single word reflecting the drug sensitivity of WIKI4 on the cell line: Sensitive."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ZG-10. The drug SMILES structure is O=C(C1=CC=C(NC(C=CCN(C)C)=O)C=C1)NC2=CC(NC3=NC(C4=CC=CN=C4)=CC=N3)=CC=C2. Drug target is JNK1. Drug target pathway is JNK and p38 signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of ZG-10 on the given cell line is:

Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAZOPANIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N. Drug target is CSF1R, KIT,  PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PAZOPANIB on the cell line with the given mutations is likely to be Resistant.

The drug targets CSF1R, KIT, PDGFRA, and PDGFRB, which are all receptor tyrosine kinases (RTKs) that play a role in cell signaling pathways. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which are all genes that are involved in cell signaling and regulation. However, none of these mutations are in the genes targeted by PAZOPANIB, suggesting that the drug is unlikely to be effective against the cell line. Therefore, the drug sensitivity is predicted to be Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BUPARLISIB. The drug SMILES structure is C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4. Drug target is PI3Kalpha, PI3Kdelta, PI3Kbeta, PI3Kgamma. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of BUPARLISIB on the cell line as Sensitive.

The drug targets PI3Kalpha, PI3Kdelta, PI3Kbeta, and PI3Kgamma, which are all involved in the PI3K/MTOR signaling pathway. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which do not seem to affect the PI3K/MTOR pathway directly. Therefore, it is likely that the drug will still be effective in inhibiting the PI3K/MTOR pathway in this cell line, making it sensitive to the drug."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALPELISIB. The drug SMILES structure is CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F. Drug target is PI3Kalpha. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of ALPELISIB on the given cell line is:

Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of CAY10566 on the cell line with the given mutations is Resistant.

The drug targets Stearoyl-CoA desaturase, which is not directly related to the given mutations in the cell line. Therefore, it is unlikely that the drug will be effective against the cell line.

Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LDN-193189. The drug SMILES structure is C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3. Drug target is BMP. Drug target pathway is Other.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of LDN-193189 on the cell line as Sensitive.

The drug targets BMP, which is a signaling pathway that plays a crucial role in various cellular processes, including cell growth, differentiation, and survival. The cell line has mutations in genes such as ARID1A, CARD11, CDKN2C, and JAK1, which are involved in various cellular processes and signaling pathways. However, none of these mutations are directly related to the BMP signaling pathway.

Therefore, it is likely that the cell line is sensitive to LDN-193189, as the drug targets a pathway that is not affected by the mutations present in the cell line."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JQ1-(+). The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JQ1-(+) as Sensitive.

The drug targets Unknown, and the cell line mutations include ARID1A, CARD11, CDKN2C, and JAK1. These mutations do not suggest any obvious resistance to the drug, and therefore, it is likely that the drug will be effective against the cell line.

Therefore, the answer is: Sensitive."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EPZ-5676. The drug SMILES structure is CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would classify the drug sensitivity of EPZ-5676 on the cell line with the given mutations as Sensitive.

The drug EPZ-5676 is a DOT1L inhibitor, and the cell line has a mutation in the DOT1L gene. This mutation is likely to affect the expression or activity of the DOT1L protein, which is a histone methyltransferase that plays a role in regulating chromatin structure and gene expression. Inhibition of DOT1L by EPZ-5676 may be particularly effective in this cell line due to the mutation, as it may disrupt the normal regulation of chromatin methylation and increase the dependence of the cell line on DOT1L activity.

Therefore, I would predict that the cell line with the given mutations would be sensitive to treatment with EPZ-5676."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VINCRISTINE. The drug SMILES structure is CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would classify the drug sensitivity of VINCRISTINE on the cell line with the given mutations as Resistant.

The drug targets Unknown, and the drug target pathway is Unknown, which suggests that the drug's mechanism of action is not well understood. Additionally, the cell line has mutations in genes such as ARID1A, CARD11, CDKN2C, and JAK1, which may confer resistance to the drug.

Therefore, in a single word, the drug sensitivity of VINCRISTINE on the cell line with the given mutations would be Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CETUXIMAB. The drug SMILES structure is CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of CETUXIMAB on the cell line with the given mutations is likely to be Sensitive.

The drug targets EGFR, which is a key player in the EGFR signaling pathway. The cell line has a mutation in JAK1, which is a downstream target of EGFR. The activation of EGFR can lead to the activation of JAK1, which can promote cell proliferation and survival. The drug's ability to target EGFR and inhibit its activity can potentially overcome the resistance caused by the JAK1 mutation, making the drug sensitive to the cell line.

Therefore, the answer is:

Drug Sensitivity: Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EHT-1864. The drug SMILES structure is C1COCCN1CC2=CC(=O)C(=CO2)OCCCCCSC3=C4C=CC(=CC4=NC=C3)C(F)(F)F.Cl.Cl. Drug target is RAC1, RAC2, RAC3. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of EHT-1864 on the given cell line is:

Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is JNJ-38877605. The drug SMILES structure is CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of JNJ-38877605 on the cell line with the given mutations as Resistant.

The drug's target pathway is Unknown, and it does not seem to be related to any of the mutated genes in the cell line. The cell line has mutations in genes such as ARID1A, CARD11, CDKN2C, and JAK1, which are not known to be involved in the drug's target pathway. Therefore, it is unlikely that the drug will be effective on this cell line.

Hence, the drug sensitivity of JNJ-38877605 on the cell line with the given mutations is Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-XII-47. The drug SMILES structure is CN1C=C(C=N1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC6=C(CCN6C(=O)C=C)C=C5. Drug target is BTK, BMX. Drug target pathway is Other, kinases.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of QL-XII-47 on the cell line with the given mutations is Resistant.

The drug targets BTK and BMX, which are involved in the B-cell receptor signaling pathway. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which are involved in various cellular processes, including cell cycle regulation, DNA damage response, and signaling pathways. However, none of these mutations are directly related to the drug target or its downstream effects. Therefore, it is likely that the drug will not be effective in this cell line, and the drug sensitivity is Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ960. The drug SMILES structure is CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F. Drug target is JAK2, JAK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of AZ960 on the cell line as Resistant.

The drug targets JAK2 and JAK3, which are involved in the JAK-STAT signaling pathway. The cell line has a mutation in JAK1, which is a member of the same signaling pathway. This suggests that the cell line may have developed resistance to the drug through mutations in the target pathway. Additionally, the cell line has mutations in other genes that may also contribute to resistance, such as ARID1A, CARD11, and CDKN2C.

Therefore, based on the available information, I would classify the drug sensitivity of AZ960 on the cell line as Resistant."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FH-535. The drug SMILES structure is CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would predict the drug sensitivity of FH-535 on the cell line with the given mutations to be Sensitive.

The drug targets Unknown, and the drug's mechanism of action is Unknown. Therefore, it's difficult to predict whether the drug will be effective on the cell line. However, based on the given mutations, it seems that the cell line has mutations in genes that are involved in various cellular processes, including DNA damage response, cell cycle regulation, and signaling pathways.

ARID1A, CARD11, CDKN2C, and JAK1 are all genes that have been implicated in cancer development and progression. The presence of these mutations suggests that the cell line may be more susceptible to drugs that target these pathways.

Therefore, I would predict that FH-535 will be effective on this cell line, and the drug sensitivity will be Sensitive."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WEHI-539. The drug SMILES structure is C1CC2=C(C=C(C=C2)C3=NC(=C(S3)CCCOC4=CC=C(C=C4)CN)C(=O)O)C(=NNC5=NC6=CC=CC=C6S5)C1.Cl. Drug target is BCL-XL. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of WEHI-539 on the given cell line is:

Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YM-201636 on the cell line with the given mutations as Sensitive.

The drug targets PIKFYVE, which is a key regulator of the PI3K/MTOR signaling pathway. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which are all genes that play roles in the PI3K/MTOR pathway. These mutations may enhance the activity of the drug and increase its effectiveness in inhibiting the PI3K/MTOR pathway. Therefore, I would predict that the drug would be sensitive on this cell line."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SHIKONIN. The drug SMILES structure is CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C. Drug target is not defined. Drug target pathway is Other.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ARA-G. The drug SMILES structure is C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N=C(NC2=O)N. Drug target is Anti-metabolite. Drug target pathway is Other.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of ARA-G on the cell line with mutations in ARID1A, CARD11, CDKN2C, and JAK1 would be:

Sensitive"
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CZC24832. The drug SMILES structure is CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C2=CN3C(=NC(=N3)N)C(=C2)F. Drug target is PI3Kgamma. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of CZC24832 on the cell line with the given mutations is likely to be Sensitive.

The drug targets PI3Kgamma, which is a key regulator of the PI3K/MTOR signaling pathway. The cell line has mutations in ARID1A, CARD11, CDKN2C, and JAK1, which are all involved in the regulation of this pathway. The presence of these mutations suggests that the cell line may have increased activity in the PI3K/MTOR pathway, making it more sensitive to inhibition by CZC24832.

Therefore, the drug sensitivity of CZC24832 on this cell line is likely to be Sensitive."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is VENETOCLAX. The drug SMILES structure is CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C. Drug target is BCL2. Drug target pathway is Apoptosis regulation.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of VENETOCLAX on the cell line with the given mutations is likely to be Sensitive.

The drug targets BCL2, which is a key regulator of apoptosis. The cell line has mutations in genes that are involved in the same pathway as BCL2, such as ARID1A, CARD11, CDKN2C, and JAK1. These mutations may enhance the activity of BCL2, making the cell line more sensitive to the inhibitory effects of VENETOCLAX.

Therefore, the drug sensitivity of VENETOCLAX on this cell line is likely to be Sensitive."
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is ALISERTIB. The drug SMILES structure is COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC. Drug target is AURKA. Drug target pathway is Mitosis.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000078,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WYE-125132. The drug SMILES structure is CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7. Drug target is mTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ARID1A, CARD11, CDKN2C, JAK1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of WYE-125132 on the cell line with mutations in ARID1A, CARD11, CDKN2C, and JAK1 would be ""Sensitive"".

The drug WYE-125132 targets mTOR, which is a key regulator of cell growth and metabolism, and is often overactivated in cancer cells. The cell line mutations in ARID1A, CARD11, CDKN2C, and JAK1 are all involved in cell signaling pathways that interact with mTOR. Specifically, ARID1A is a tumor suppressor that regulates mTOR activity, while CARD11 and CDKN2C are involved in the regulation of cell cycle progression and DNA damage response, which can also impact mTOR activity. JAK1 is a tyrosine kinase that can activate mTOR signaling.

Given the role of these mutations in regulating mTOR activity, it is likely that the cell line with these mutations would be sensitive to treatment with WYE-125132, which targets mTOR. Therefore, my answer would be ""Sensitive""."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CUDC-101. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO. Drug target is HDAC1-10, EGFR, ERBB2. Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of CUDC-101 on the cell line with the given mutations is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IMATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL, KIT, PDGFR. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of IMATINIB on the cell line with the given mutations is Resistant.

The drug targets ABL, KIT, and PDGFR, which are kinases. However, the cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, and WT1, which are not directly related to the drug's target pathway. Therefore, it is likely that the drug will not be effective in inhibiting the activity of its target proteins, leading to resistance."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FTI-277. The drug SMILES structure is COC(=O)[C@H](CCSC)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC=C2. Drug target is Farnesyl-transferase (FNTA). Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of FTI-277 on the cell line as Resistant.

The drug targets Farnesyl-transferase (FNTA), which is not a key player in the cell cycle or mitosis pathways, and the cell line mutations do not suggest a clear reason for the drug to be sensitive. Additionally, the drug's mechanism of action, which involves inhibiting farnesylation of proteins, may not be affected by the mutations present in the cell line. Therefore, I would predict that the drug would be resistant to the cell line."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KIN001-244. The drug SMILES structure is C1=CC=C(C=C1)[C@H](COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F. Drug target is PDK1. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of KIN001-244 on the cell line with the given mutations is Sensitive.

The drug targets PDK1, which is a key regulator of cellular signaling pathways, including the PI3K/Akt pathway. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are known to be involved in various cellular signaling pathways. However, none of these mutations are known to directly affect the PDK1 pathway.

Therefore, it is likely that the drug will be effective in inhibiting the PDK1 target and inducing cell death in this cell line, regardless of the presence of these mutations. Hence, the drug sensitivity is predicted to be Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PAZOPANIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N. Drug target is CSF1R, KIT,  PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of PAZOPANIB on the cell line with the given mutations is Resistant.

The drug targets CSF1R, KIT, PDGFRA, and PDGFRB, which are all receptor tyrosine kinases (RTKs) that play a role in cell signaling pathways. However, the cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the drug target pathway. Therefore, it is likely that the drug will not be effective in inhibiting the activity of the mutated proteins, leading to resistance.

Therefore, the answer is:

Drug Sensitivity: Resistant"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OXALIPLATIN. The drug SMILES structure is C1CC[C@H]([C@@H](C1)N)N.C(=O)(C(=O)O)O.[Pt]. Drug target is DNA alkylating agent. Drug target pathway is DNA replication.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of OXALIPLATIN on the cell line with the given mutations as Resistant.

The drug OXALIPLATIN is a DNA alkylating agent that works by damaging the DNA, which leads to cell death. The drug target is DNA replication, and it is not specific to any particular protein or pathway.

The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1. These mutations may not directly affect the drug target or pathway, but they could potentially impact the cell's ability to repair DNA damage, which could affect the drug's efficacy.

Without further information or context, it is difficult to determine the exact mechanism by which these mutations might affect the drug's sensitivity. However, based on the available information, it seems likely that the cell line's mutations would confer resistance to OXALIPLATIN, as the drug relies on the proper functioning of DNA replication and repair mechanisms to be effective. Therefore, I would classify the drug sensitivity of OXALIPLATIN on this cell line as Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CAY10566. The drug SMILES structure is CC1=NN=C(O1)C2=NN=C(C=C2)N3CCC(CC3)OC4=C(C=CC(=C4)F)Cl. Drug target is Stearoyl-CoA desaturase. Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of CAY10566 on the cell line as Sensitive.

The drug targets Stearoyl-CoA desaturase, which is not a well-known drug target, and the cell line has mutations in genes that are not directly related to the drug target pathway. Therefore, it is likely that the drug will be effective against the cell line, and the sensitivity is Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is UNC0642. The drug SMILES structure is CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)N5CCC(CC5)(F)F. Drug target is G9A, GLP. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of UNC0642 on the given cell line is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DOXORUBICIN. The drug SMILES structure is C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O. Drug target is Anthracycline. Drug target pathway is DNA replication.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of DOXORUBICIN on the cell line with the given mutations is Resistant.

The drug targets the Anthracycline pathway, which is involved in DNA replication. The cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the Anthracycline pathway. Therefore, it is likely that the drug will still be effective in inhibiting DNA replication and causing cell death in this cell line, despite the presence of these mutations.

Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WHI-P97. The drug SMILES structure is COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C(=C3)Br)O)Br)OC. Drug target is JAK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of WHI-P97 on the given cell line is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD5363. The drug SMILES structure is O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO. Drug target is AKT1, AKT2, AKT3, ROCK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of AZD5363 on the cell line with mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1 would be ""Sensitive"".

The drug AZD5363 targets AKT1, AKT2, AKT3, and ROCK2, which are all involved in the PI3K/AKT signaling pathway. The cell line has mutations in ERBB4, GNAS, and NOTCH1, which are also involved in this pathway. Therefore, it is likely that the drug will be effective in inhibiting the activity of these proteins and inducing cell death in this cell line.

Additionally, the cell line has a mutation in SDHA, which is involved in the mitochondrial electron transport chain and can affect the cell's ability to produce energy. The drug AZD5363 has been shown to inhibit the activity of SDHA, which could further contribute to its effectiveness in this cell line.

Overall, based on the available information, it is predicted that AZD5363 would be sensitive in this cell line."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is REFAMETINIB. The drug SMILES structure is COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F. Drug target is MEK1, MEK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of REFAMETINIB on the cell line with the given mutations is Resistant.

The drug targets MEK1 and MEK2, which are downstream of the ERK MAPK signaling pathway. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the ERK MAPK pathway. Therefore, it is likely that the drug will not be effective in inhibiting the ERK MAPK pathway and will not show significant activity against the cell line.

Hence, the drug sensitivity of REFAMETINIB on the cell line with the given mutations is Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is XMD14-99. The drug SMILES structure is CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC(=C(S3)C(=O)C4=C(C=CC=C4Cl)Cl)N)OC. Drug target is ALK, CDK7, LTK, others. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of XMD14-99 on the cell line with the given mutations is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MPS-1-IN-1. The drug SMILES structure is CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC. Drug target is MPS1. Drug target pathway is Mitosis.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of MPS-1-IN-1 on the cell line as Resistant.

The drug targets the MPS1 pathway, which is involved in mitosis. The cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the MPS1 pathway. Therefore, it is likely that the drug will not be effective in inhibiting the MPS1 pathway in this cell line, leading to resistance."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is EX-527. The drug SMILES structure is C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N. Drug target is SIRT1. Drug target pathway is Chromatin histone acetylation.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of EX-527 on the cell line with the given mutations is:

Sensitive

Reasoning:

* EX-527 is a SIRT1 inhibitor, and SIRT1 is a key regulator of chromatin histone acetylation.
* The cell line has mutations in genes that are involved in chromatin histone acetylation, such as NOTCH1 and SPEN.
* Inhibition of SIRT1 by EX-527 may be particularly effective in this cell line because of the presence of these mutations, which could make the cell line more dependent on SIRT1 activity.
* Therefore, I predict that EX-527 will be sensitive on this cell line."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TALAZOPARIB. The drug SMILES structure is CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F. Drug target is PARP1, PARP2. Drug target pathway is Genome integrity.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of TALAZOPARIB on the given cell line is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GEFITINIB. The drug SMILES structure is COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of GEFITINIB on the cell line is Sensitive.

The drug targets EGFR, which is mutated in the cell line, and the drug's target pathway is EGFR signaling. The presence of the mutation in the EGFR gene suggests that the cell line is likely to be sensitive to the drug. Therefore, the drug sensitivity is labeled as Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SALUBRINAL. The drug SMILES structure is C1=CC=C(C=C1)C=CC(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3. Drug target is EIF2A. Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would classify the drug sensitivity of SALUBRINAL on the given cell line as Resistant.

The drug targets EIF2A, which is not a commonly mutated gene in cancer cells. Moreover, the cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, and WT1, which are not known to be involved in EIF2A signaling. Therefore, it is unlikely that the drug will be effective in this cell line.

Hence, the answer is Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FLUDARABINE. The drug SMILES structure is C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N. Drug target is Antimetabolite. Drug target pathway is DNA replication.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of FLUDARABINE on the cell line with mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1 would be ""Sensitive"".

The drug targets DNA replication, and the mutations in the cell line do not affect the drug's target pathway. Therefore, the drug is likely to be effective in inhibiting DNA replication and killing the cancer cells.

So, the answer would be:

Drug Sensitivity: Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD3759. The drug SMILES structure is C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C. Drug target is EGFR. Drug target pathway is EGFR signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of AZD3759 on the given cell line is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK269962. The drug SMILES structure is CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6. Drug target is ROCK1, ROCK2. Drug target pathway is Cytoskeleton.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,Sensitive
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is DMOG. The drug SMILES structure is COC(=O)CNC(=O)C(=O)OC. Drug target is HIF-PH. Drug target pathway is Metabolism.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of DMOG on the cell line as Resistant.

The drug target of DMOG is HIF-PH, which is involved in the metabolism pathway. The cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the HIF-PH pathway. Therefore, it is likely that the cell line is resistant to DMOG treatment."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is OTX015. The drug SMILES structure is CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C. Drug target is BRD2, BRD3, BRD4. Drug target pathway is Chromatin other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of OTX015 on the cell line with the given mutations is Resistant.

The drug targets BRD2, BRD3, and BRD4, which are involved in chromatin remodeling and transcriptional regulation. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are not directly related to the drug target pathway. Therefore, it is likely that the drug will not be effective in this cell line, resulting in resistance."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is YM-201636. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N. Drug target is PIKFYVE. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of YM-201636 on the cell line as Sensitive.

The drug targets PIKFYVE, which is a key regulator of the PI3K/MTOR signaling pathway. The cell line has mutations in several genes that are involved in this pathway, including ERBB4, NOTCH1, and PTEN. These mutations may enhance the activity of the PI3K/MTOR pathway and increase the dependence of the cell line on this pathway for survival.

YM-201636, as a PIKFYVE inhibitor, would likely inhibit the activity of this pathway and potentially induce cell death in the cell line. Therefore, I would predict that the drug sensitivity of YM-201636 on the cell line is Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is NSC-319726. The drug SMILES structure is CC(=NNC(=S)N1CCC1)C2=CC=CC=N2. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of NSC-319726 on the cell line with the given mutations as Resistant.

The drug's target pathway is Unknown, and it does not seem to be related to any of the mutated genes in the cell line. Therefore, it is unlikely that the drug would be effective in inhibiting the growth of this cell line.

Here's my reasoning:

* ERBB4: This gene is involved in the PI3K/AKT signaling pathway, which is not related to the drug's target pathway.
* GNAS: This gene is involved in the G-protein signaling pathway, which is not related to the drug's target pathway.
* NOTCH1: This gene is involved in the Notch signaling pathway, which is not related to the drug's target pathway.
* SDHA: This gene is involved in the mitochondrial electron transport chain, which is not related to the drug's target pathway.
* SPEN: This gene is involved in the splicing of messenger RNA, which is not related to the drug's target pathway.
* WT1: This gene is involved in the Wnt signaling pathway, which is not related to the drug's target pathway.

Therefore, based on the information provided, it seems unlikely that NSC-319726 would be effective in inhibiting the growth of this cell line, and I would classify its drug sensitivity as Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is PI-103. The drug SMILES structure is C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O. Drug target is PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of PI-103 on the cell line as Resistant.

The drug targets multiple kinases, including PI3Kalpha, DAPK3, CLK4, PIM3, and HIPK2. However, the cell line has mutations in several genes that are involved in the PI3K/AKT signaling pathway, including GNAS, NOTCH1, and PTEN. These mutations may confer resistance to the drug by altering the signaling pathway and reducing its effectiveness. Additionally, the cell line has a mutation in SDHA, which is involved in the mitochondrial electron transport chain and may also contribute to resistance.

Therefore, based on the available information, I would predict that PI-103 would be resistant to the cell line."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LEFLUNOMIDE. The drug SMILES structure is CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F. Drug target is Pyrimidine synthesis inhibitor. Drug target pathway is DNA replication.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LEFLUNOMIDE on the cell line with mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1 would be ""Sensitive"".

The drug target of LEFLUNOMIDE is pyrimidine synthesis inhibitor, which is involved in DNA replication. The cell line has mutations in genes related to DNA replication and repair, such as ERBB4, GNAS, and SDHA. These mutations may increase the dependence of the cell line on pyrimidine synthesis, making it more sensitive to inhibition by LEFLUNOMIDE. Additionally, the presence of mutations in NOTCH1 and WT1, which are involved in cell proliferation and differentiation, may also contribute to the sensitivity of the cell line to LEFLUNOMIDE.

Therefore, based on the available information, it is likely that LEFLUNOMIDE would be effective in inhibiting the growth of this cell line, and the drug sensitivity would be classified as ""Sensitive""."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is FORETINIB. The drug SMILES structure is COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F. Drug target is MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR. Drug target pathway is RTK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of FORETINIB on the cell line with the given mutations is Resistant.

The drug targets multiple receptors involved in RTK signaling, including MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, and EGFR. However, the cell line has mutations in genes that are downstream of these receptors, such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1. These mutations may confer resistance to the drug by disrupting the signaling pathways that the drug targets. Therefore, the drug sensitivity of FORETINIB on this cell line is Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MASITINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5. Drug target is KIT, PDGFRA, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of MASITINIB on the cell line with the given mutations is likely to be Sensitive.

The drug targets KIT, PDGFRA, and PDGFRB, which are all involved in RTK signaling. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are all genes that play a role in RTK signaling or downstream effects. Therefore, it is likely that the drug will be effective in inhibiting the activity of the mutated genes and pathways, leading to sensitive drug sensitivity."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is GSK1059615. The drug SMILES structure is C1=CC2=NC=CC(=C2C=C1C=C3C(=O)NC(=O)S3)C4=CC=NC=C4. Drug target is PI3K. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of GSK1059615 on the cell line with the given mutations is Resistant.

The drug targets PI3K, which is a key regulator of cell survival and proliferation. The cell line has mutations in several genes that are involved in the PI3K/MTOR signaling pathway, including PI3K itself, NOTCH1, and SDHA. These mutations may confer resistance to the drug by altering the activity of the target protein or downstream signaling pathways.

Therefore, the drug sensitivity of GSK1059615 on this cell line is Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is QL-VIII-58. The drug SMILES structure is NC1=NC=C(C=N1)C1=CC=C2N=CC3=C(N(C(=O)C=C3)C3=CC(Cl)=C(C=C3)N3CCNCC3)C2=C1. Drug target is MTOR, ATR. Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of QL-VIII-58 on the cell line with the given mutations is Sensitive.

The drug targets MTOR and ATR, which are both involved in the PI3K/MTOR signaling pathway. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are all genes that play roles in various cellular processes, including cell signaling, metabolism, and gene regulation. However, none of these mutations are in the direct target genes of QL-VIII-58, MTOR and ATR. Therefore, it is likely that the drug will still be effective in inhibiting its target proteins and producing a therapeutic effect.

Therefore, the drug sensitivity of QL-VIII-58 on this cell line is Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is MK-8776. The drug SMILES structure is CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4. Drug target is CHEK1, CHEK2, CDK2. Drug target pathway is Cell cycle.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of MK-8776 on the cell line with the given mutations is Resistant."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD4547. The drug SMILES structure is C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC. Drug target is FGRF1, FGFR2, FGFR3. Drug target pathway is RTK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of AZD4547 on the cell line with the given mutations is Sensitive.

The drug targets FGFR1, FGFR2, and FGFR3, which are involved in the RTK signaling pathway. The cell line has mutations in ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1. These mutations do not seem to affect the drug's target or pathway, and therefore, the drug is likely to be effective against the cell line.

Therefore, the answer is: Sensitive."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CEDIRANIB. The drug SMILES structure is CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5. Drug target is VEGFR, FLT1, FLT2, FLT3, FLT4, KIT, PDGFRB. Drug target pathway is RTK signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of CEDIRANIB on the given cell line is:

Sensitive"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BRYOSTATIN-1. The drug SMILES structure is CCCC=CC=CC(=O)OC1C(=CC(=O)OC)CC2CC(OC(=O)CC(CC3CC(C(C(O3)(CC4CC(=CC(=O)OC)CC(O4)C=CC(C1(O2)O)(C)C)O)(C)C)OC(=O)C)O)C(C)O. Drug target is Unknown. Drug target pathway is Unknown.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of BRYOSTATIN-1 on the cell line with the given mutations is unknown.

The drug targets Unknown, and its target pathway is also Unknown. Therefore, it is not possible to determine whether the drug will be effective on the cell line with the given mutations.

It's important to note that drug sensitivity can be influenced by many factors, including the specific mutations present in the cell line, the expression levels of drug targets, and the presence of other genetic alterations that may affect drug response. Therefore, it's not always possible to predict drug sensitivity based solely on the mutations present in the cell line.

In this case, further experiments or analysis would be needed to determine the drug sensitivity of BRYOSTATIN-1 on the cell line with the given mutations."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is WYE-125132. The drug SMILES structure is CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7. Drug target is mTOR. Drug target pathway is PI3K/MTOR signaling.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of WYE-125132 on the cell line as Resistant.

The drug targets mTOR, which is a key regulator of cell growth and metabolism, and the cell line has mutations in genes that are downstream of mTOR, such as NOTCH1 and SDHA. These mutations may confer resistance to the drug by altering the cell's ability to respond to mTOR inhibition. Additionally, the cell line has a mutation in GNAS, which is a gene that regulates the activity of mTOR, and this mutation may also contribute to resistance.

Therefore, based on the available information, I would predict that WYE-125132 would be resistant to the cell line."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is KB NB 142-70. The drug SMILES structure is C1CSC2=C(C(=O)N1)SC3=C2C=C(C=C3)O. Drug target is PKD. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of KB NB 142-70 on the cell line as Sensitive.

The drug targets PKD, which is a kinase that plays a role in various cellular processes, including cell signaling and protein synthesis. The cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are involved in signaling pathways that interact with PKD.

Therefore, it is likely that the drug will be effective in inhibiting PKD activity in this cell line, leading to sensitive drug sensitivity."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is CPI-613. The drug SMILES structure is C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2. Drug target is Metabo, Mitochondria. Drug target pathway is Other.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of CPI-613 on the cell line as Resistant.

The drug targets the mitochondrial metabolism pathway, which is not directly related to the provided mutations in the cell line. The mutations in the cell line are primarily related to signaling pathways, such as the ERBB4, NOTCH1, and WT1 mutations. Therefore, it is unlikely that the drug would be effective in targeting the mitochondrial metabolism pathway in this cell line, resulting in resistance to the drug."
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SPHINGOSINE KINASE 1 INHIBITOR II. The drug SMILES structure is CC1=CC(=CC(=C1)OCC2=CC=C(C=C2)CN3CCC[C@@H]3CO)CS(=O)(=O)C4=CC=CC=C4. Drug target is Sphingosine Kinase. Drug target pathway is Other, kinases.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of SPHINGOSINE KINASE 1 INHIBITOR II on the cell line with the given mutations as Resistant.

The drug targets Sphingosine Kinase, which is not directly related to any of the mutated genes. Moreover, the drug's pathway, Other, kinases, does not seem to be affected by the mutations either. Therefore, it is likely that the drug will not be effective on this cell line.

So, the answer would be:

Drug Sensitivity: Resistant"
ACH-000105,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SGC0946. The drug SMILES structure is CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)CC2C(C(C(O2)N3C=C(C4=C(N=CN=C43)N)Br)O)O. Drug target is DOT1L. Drug target pathway is Chromatin histone methylation.
The mutations of the cell line are ERBB4, GNAS, NOTCH1, SDHA, SPEN, WT1.
Drug Sensitivity: ?",Resistant,"Based on the information provided, the drug sensitivity of SGC0946 on the cell line with the given mutations is Sensitive.

The drug SGC0946 targets DOT1L, which is a histone methyltransferase that plays a role in regulating chromatin structure and gene expression. The cell line has mutations in genes such as ERBB4, GNAS, NOTCH1, SDHA, SPEN, and WT1, which are known to be involved in various cellular processes, including cell signaling, differentiation, and survival.

However, none of these mutations are known to directly affect the activity of DOT1L or the chromatin histone methylation pathway. Therefore, it is likely that the drug SGC0946 will still be effective in inhibiting DOT1L and inducing cell death in this cell line, regardless of the presence of these mutations.

Therefore, the drug sensitivity of SGC0946 on this cell line is classified as Sensitive."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AGI-6780. The drug SMILES structure is C1CC1NS(=O)(=O)C2=CC(=C(C=C2)C3=CSC=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F. Drug target is IDH2(R140Q). Drug target pathway is Metabolism.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of AGI-6780 on the cell line as Resistant.

The drug targets IDH2(R140Q) and the cell line has a mutation in KRAS, which is a downstream target of IDH2. This suggests that the cell line may have developed resistance to the drug through the KRAS mutation. Additionally, the cell line has mutations in other genes such as ABL1, CDKN2A, FANCC, RNF43, and TP53, which may also contribute to resistance to the drug.

Therefore, in a single word, the drug sensitivity of AGI-6780 on the cell line would be Resistant."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZD8931. The drug SMILES structure is CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC. Drug target is EGFR, ERBB2, ERBB3. Drug target pathway is RTK signaling.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of AZD8931 on the cell line with the given mutations is:

Sensitive"
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is IMATINIB. The drug SMILES structure is CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5. Drug target is ABL, KIT, PDGFR. Drug target pathway is Other, kinases.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of IMATINIB on the cell line with the given mutations is likely to be Resistant.

The drug targets ABL, KIT, and PDGFR, which are all kinases. However, the cell line has a mutation in the KRAS gene, which is a downstream target of the PI3K/AKT pathway, which is activated by ABL, KIT, and PDGFR. The KRAS mutation can cause the PI3K/AKT pathway to be constitutively activated, making the cell line less dependent on the activity of ABL, KIT, and PDGFR. Therefore, inhibition of these kinases by IMATINIB may not have a significant effect on the cell line's proliferation.

Additionally, the cell line has a mutation in the TP53 gene, which is a tumor suppressor gene that regulates cell cycle and apoptosis. The mutation in TP53 can lead to the loss of cell cycle regulation and increased resistance to chemotherapy.

Therefore, based on the drug target and the mutations present in the cell line, it is likely that IMATINIB will be less effective in inhibiting the proliferation of this cell line, and the drug sensitivity is predicted to be Resistant."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINSITINIB. The drug SMILES structure is CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O. Drug target is IGF1R. Drug target pathway is IGF1R signaling.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LINSITINIB on the cell line with the given mutations is likely to be Resistant.

The drug targets IGF1R, which is a key regulator of cell growth and survival. However, the cell line has mutations in several genes that are involved in the PI3K/AKT signaling pathway, including KRAS, RNF43, and TP53. These mutations can activate the PI3K/AKT pathway and promote cell survival, making the cells less sensitive to the inhibitory effects of LINSITINIB on IGF1R.

Therefore, the drug sensitivity of LINSITINIB on this cell line is likely to be Resistant."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LINIFANIB. The drug SMILES structure is CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N. Drug target is VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LINIFANIB on the cell line with the given mutations is Resistant.

The drug targets VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, and KIT, which are all involved in RTK signaling. However, the cell line has mutations in ABL1, CDKN2A, FANCC, KRAS, RNF43, and TP53, which are known to confer resistance to drugs that target RTK signaling. Therefore, it is likely that the cell line will be resistant to LINIFANIB."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LFM-A13. The drug SMILES structure is CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O. Drug target is BTK. Drug target pathway is Other, kinases.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of LFM-A13 on the cell line as Resistant.

The drug targets BTK, which is a kinase that plays a crucial role in B-cell signaling. The cell line has mutations in several genes, including KRAS, TP53, and FANCC, which are known to be involved in cancer development and progression. However, none of these mutations are known to directly affect the BTK pathway or the sensitivity of the cell line to LFM-A13.

Therefore, based on the available information, it is likely that the cell line would be resistant to LFM-A13, as the drug targets a pathway that is not directly affected by the mutations present in the cell line."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TIVOZANIB. The drug SMILES structure is CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl. Drug target is VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT. Drug target pathway is RTK signaling.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, my answer for the drug sensitivity of TIVOZANIB on the given cell line is:

Sensitive"
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is LESTAURTINIB. The drug SMILES structure is C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O. Drug target is FLT3, JAK2, NTRK1, NTRK2, NTRK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, the drug sensitivity of LESTAURTINIB on the cell line with the given mutations is Resistant."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is BVD-523. The drug SMILES structure is CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl. Drug target is ERK1, ERK2. Drug target pathway is ERK MAPK signaling.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, I would determine the drug sensitivity of BVD-523 on the cell line as Resistant.

The drug targets ERK1 and ERK2, which are key players in the ERK MAPK signaling pathway. However, the cell line has mutations in several genes that are also involved in this pathway, including KRAS and TP53. These mutations may confer resistance to the drug by altering the signaling pathway and reducing its effectiveness. Additionally, the drug's mechanism of action, which involves inhibiting the activity of ERK1 and ERK2, may not be effective in the presence of these mutations. Therefore, I would predict that the drug would be resistant to the cell line."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is TANESPIMYCIN. The drug SMILES structure is CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC. Drug target is HSP90. Drug target pathway is Protein stability and degradation.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Resistant,"Based on the information provided, my answer for the drug sensitivity of TANESPIMYCIN on the given cell line is:

Sensitive"
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is SALUBRINAL. The drug SMILES structure is C1=CC=C(C=C1)C=CC(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=CC3=C2N=CC=C3. Drug target is EIF2A. Drug target pathway is Other.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,"Based on the information provided, I would determine the drug sensitivity of SALUBRINAL on the cell line as Resistant.

The drug targets EIF2A, which is not a commonly mutated gene in cancer cells. Therefore, it is unlikely that the cell line would have a mutation in EIF2A that would confer resistance to the drug. Additionally, the cell line has mutations in genes such as KRAS and TP53, which are commonly mutated in cancer cells and may contribute to resistance to the drug. Therefore, based on the available information, it is likely that the cell line would be resistant to SALUBRINAL."
ACH-000107,"Think step by step and decide in a single word reflecting the drug sensitivity of the drug on the cell line with given mutations: [Sensitive/Resistant], [Reasoning].
Drug and cell line mutations: 
The drug is AZ960. The drug SMILES structure is CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F. Drug target is JAK2, JAK3. Drug target pathway is Other, kinases.
The mutations of the cell line are ABL1, CDKN2A, FANCC, KRAS, RNF43, TP53.
Drug Sensitivity: ?",Sensitive,Sensitive
